GlassScriptPhysician profile
Michael Daunov
NPI 1841796372
$1,902.37
in general payments reported to CMS, 2019-2025
29 companies · $607 in 2025
The $607 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.25 · 2023: $484 · 2024: $775 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,865.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $264.98 | 2023-2025 | |
| Pfizer INC. | $157.14 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $153.51 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.04 | 2023-2025 | Fruzaqla, Alunbrig |
| Blueprint Medicines Corporation | $113.56 | 2023-2025 | Ayvakit |
| Astrazeneca Pharmaceuticals LP | $96.10 | 2024-2025 | Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $90.61 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $83.40 | 2024-2025 | Enhertu |
| Incyte Corporation | $81.19 | 2023-2024 | Jakafi |
| Eisai INC. | $78.41 | 2023-2024 | |
| Beone Medicines USA, INC. | $64.60 | 2025 | Brukinsa, Tevimbra |
| Adc Therapeutics America, INC. | $57.93 | 2024-2025 | |
| Celgene Corporation | $51.95 | 2024-2025 | Reblozyl |
| Seagen INC. | $51.38 | 2023 | Tukysa, Adcetris |
| Genmab U.S., INC. | $46.25 | 2023-2024 | Epkinly, Tivdak |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $41.01 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $39.48 | 2023-2024 | Zepzelca |
| Alexion Pharmaceuticals, INC. | $36.82 | 2024 | Ultomiris |
| Astellas Pharma US INC | $30.77 | 2024 | |
| Lilly USA, LLC | $26.60 | 2025 | Verzenio, Jaypirca |
| Regeneron Healthcare Solutions, INC. | $26.03 | 2023 | Libtayo |
| Agios Pharmaceuticals, INC. | $24.66 | 2025 | Pyrukynd |
| Amgen INC. | $24.34 | 2023 | Lumakras |
| Sobi, INC | $20.42 | 2025 | |
| Gilead Sciences, INC. | $19.98 | 2024 | |
| Array Biopharma INC | $19.66 | 2022 | |
| Beigene USA, INC. | $18.31 | 2023 | Brukinsa |
| Kite Pharma, INC. | $16.45 | 2023 | Yescarta |
| Springworks Therapeutics, INC. | $13.79 | 2024 | Ogsiveo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Daunov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.